ALDR Company Description
We are a clinical-stage biopharmaceutical company that discovers, develops and
seeks to commercialize therapeutic antibodies with the potential to meaningfully
transform current treatment paradigms. We have developed a proprietary antibody
platform designed to select antibodies that have the potential to maximize
efficacy as well as speed of onset and durability of therapeutic response. In
addition, we believe our ability to efficiently manufacture antibodies using our
yeast-based manufacturing technology, MabXpress, allows us to target diseases
that traditionally have not been addressed by antibodies. We believe the
clinical data obtained in our development program for ALD403, our wholly-owned
clinical asset, exhibits the potential of this product candidate to transform
the way physicians treat migraine prevention. Clazakizumab is being developed by
our collaboration partner Bristol-Myers Squibb. Together with Bristol-Myers
Squibb, we believe there is an opportunity to position Clazakizumab as an option
for first-line biologic therapy for the treatment of rheumatoid arthritis by
demonstrating superior disease control rates versus biologic standard of care.
The most commonly prescribed biologic standard of care are anti-TNFs, such as
Humira or Enbrel. We estimate that the rheumatoid arthritis therapy market had
more than $12 billion in worldwide sales in 2012 and will grow to $15 billion by
2016. Both our lead product candidates were discovered internally, have achieved
proof-of-concept and are expected to enter final Phase 2b dose-ranging trials in
2014 in preparation for progression to Phase 3 trials if supported by the data.
---
We were incorporated in Delaware in May 2002 as Alder BioPharmaceuticals, Inc.
Our headquarters are located at 11804 North Creek Parkway South, Bothell, WA
98011, and our telephone number is (425) 205-2900. Our website address is
www.alderbio.com.
